BioSpace News Archive

In PNEU-PATH (V114-016) and PNEU-DAY (V114-017), V114 Met Primary Immunogenicity Objectives and Elicited A Strong Immune Response for All 15 Serotypes Included in the Vaccine, Including 22F and 33F - Serotypes Unique to V114

Parexel announced that its Biotech division has entered into a strategic collaboration with Synairgen plc, a respiratory drug discovery and development company, to conduct a pivotal phase III study of an interferon beta treatment for patients hospitalized with COVID-19.

Aclaris Therapeutics, Inc. announced that the first patient has been dosed in Aclaris’ Phase 2a clinical trial of ATI-1777, an investigational topical “soft” Janus kinase 1/3 inhibitor, for the treatment of moderate to severe atopic dermatitis.

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network.

ReWalk Robotics, Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced that the Centers for Medicare & Medi

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18 F-Fluciclovine at Upcoming ASTRO Annual Meeting

- Contribution of up to $2.8 million will support clinical advancement of bacTRL-Spike™ oral vaccine candidate - Proprietary bacTRL™ platform can be used to produce vaccines that can be stored at room temperature and administered orally rather than injected

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.8 of the preeminent platform for physiologically based biopharmaceutics (PBBM) / pharmacokinetic (PBPK) modeling, GastroPlus®

Ymir Genomics LLC (Ymir) and the Oregon Health & Science University (OHSU) Knight Cancer Institute today announced a licensing agreement and filed patent application that seeks to protect and promote newly-discovered high value urinary biomarkers for detecting cirrhosis and/or hepatocellular carcinoma (HC

Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(FSE:4PC) (“Perimeter” or the “Company”), is pleased to announce a transition to new roles for two of the Company’s senior leaders with the appointment of Jeremy Sobotta as Chief Executive Officer and Tom Boon as Chief Operating Officer,